Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
NCT02114658
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Thyroid Carcinoma
Interventions
DRUG:
Sorafenib (Nexavar,BAY43-9006)
Sponsor
Bayer